U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258810) titled 'Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program' on Nov. 21.
Brief Summary: In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home. However, this way of giving treatment brings specific challenges, especially in managing side effects and making sure patients follow their treatment properly.
Because of this, many patient education programs have been created to hel...